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Original Article
Abstract
Purpose: Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2/neu) expression in
breast cancer patients predict response to chemotherapy though recorded extent vary. This retrospective study aimed to inves-
tigate the relationship between ER, PR and HER2/neu expression and response of breast cancer to chemotherapy at a tertiary
hospital in Ghana. Methods: Records of all breast cancer cases seen from 2009 through 2011 were reviewed. Their receptor sta-
tus, first line treatment [4 cycles of Adriamycin (60mg/m2) + Cyclophosphamide (600mg/m2)], second line treatment [Capecita-
bine (1g/m2) + Paclitaxel (170mg/m2)] and clinical response were extracted. Results: Complete remission after first and second
line treatments were observed in 36 (38.3%, 95% CI: 28.5 to 48.9) and 34 (58.6%, 95% CI: .44.9 to 71.4) respectively. After both
first and second line treatment 70 (74.5%, 95% CI: 64.4 - 82.9) had gone into remission. Prevalence of ER, PR, HER2/neu and
Triple negative breast cancer (TNBC) were 34.0% (95% CI: 24.6 to 44.5), 20.2% (95% CI: 12.6 to 29.7), 8.5% (95% CI: 3.7 to
16.1) and 59.6% (95%CI: 48.9 to 69.6) respectively. ER and PR positivity were independently associated with complete remis-
sion after first line treatment while TNBC was associated with non-remission. Conversely ER was independently associated
with non-remission after second line treatment while TNBC was associated with complete remission. Conclusion: ER and
TNBC status are significant predictors of complete remission and non-remission respectively after chemotherapy for breast
cancer patient in Ghana.
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Introduction
Breast cancer accounted for 23% of the total new cancer
cases in the world in 2008, making it the leading cause of
cancer deaths in females.1 According to the Global cancer
statistics in 2002, breast cancer was the most prevalent can-
cer in the world.2 Increased use of mammography screening
and early detection seems to have contributed to the decline
in the mortality rates in the developed world.3 However the
story in the developing world may be different where the
incidence and mortality rates are rising with younger wom-
en been diagnosed of the disease.4
In Ghana the age group commonly affected is between 40-49
years.5 Due to lack of education and effective screening
measures patients often present to the hospital late with ad-
vanced stages of the disease.5 There are reports of unsatisfac-
tory emotional support, communication and counselling for
the breast cancer patients in Ghana, thereby making them
resort to spiritualist and herbalist for support and treat-
ment.6,7 There is an association between age and the histo-
logical type of the breast cancer in Ghanaian women, and
the risk of the disease also increases after the age of 30 years.7
Many studies have been done on HER2/neu (an epidermal
growth factor receptor) as a predictive marker for most
chemotherapy regimens. There are conflicting reports on the
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relationship between HER2/neu and response to
neo-adjuvant anthracycline based chemotherapy 8 making it
difficult to use to determine chemotherapy treatment op-
tions. However according to Muss et al., the benefit of an
anthracycline based chemotherapy for breast cancer may be
dependent on the over expression of HER2/neu receptors.9
Available data reveal that HER2/neu over-expression is asso-
ciated with poor overall prognosis, shorter relapse-free and
overall survival time, and resistance to adjuvant anthracy-
cline chemotherapy.10-12 HER2/neu over-expression is asso-
ciated with the dose-intensity and dose-density of an an-
thracycline based chemotherapy. Thor et al., showed that
regimens of increased dose per cycle (dose intensity) of an
anthracycline based chemotherapy are associated with an
improved outcome only in women with HER2/neu over
expression.13 Also, HER2/neu is now the standard predictive
marker for transtuzumab (a humanized monoclonal anti-
body) in the treatment of breast cancer.14
Oestrogen receptor (ER) status in breast cancer has a major
role in terms of predicting response to chemotherapy. Thus,
according to the international breast cancer group, patients
with ER negative breast cancer, receiving cyclophospha-
mide, methotrexate and 5-florouracil have 48% reduction in
their risk of recurrence and a 49% reduction in the risk of
death from any cause. For patients with ER positive breast
cancer both risks were reduced by only 1%.15 In 2006, Berry
et al also showed that, twice weekly doxorubi-
cin/cyclophosphamide plus paclitaxel lowers the rate of re-
currence and death by more than 50% in ER-negative breast
cancer.16 In the neo-adjuvant setting, tumours without hor-
mone receptors are more sensitive to chemotherapy than are
hormone-sensitive tumours, with markedly higher rates of
pathological complete response.17-19 Patients with progester-
one (PR) negative breast cancer do not have good response to
chemotherapy compared to ER negative breast cancers ac-
cording to MacGrogan et al.20 Meanwhile a study done by
Colleoni et al. had shown that tumours of low expression of
PR had a significantly higher response to primary chemo-
therapy.21
Triple negative breast cancer (ER-negative, PR-negative,
HER2/neu not over expressed) is the absence of histological
staining of ERs, PRs and HER2 in a breast cancer tissue.22
The triple negative breast cancer (TNBC) is reported to re-
spond to neo-adjuvant chemotherapy 23, 24, but has a poor
prognosis compared with non-TNBC (hormone receptor
positive) patients.25 In evaluating response to neo-adjuvant
chemotherapy the MD Anderson Centre in the U.S.A from
1985 to 2005 studied the response and prognosis of 1,118
TNBC and non-TNBC patients receiving neo-adjuvant
chemotherapy. The pathological complete response rate in
the 23% of non-TNBC patients was double that of TNBC
patients. The overall 3-year freedom from progression was
63% in the TNBC and 76% in the non-TNBC groups, and the
3 year overall survival between the groups was 74% and
89%, respectively, confirming the relatively poor prognosis
in TNBC.25
Published data on breast cancer in Ghana is scarce and for
that matter knowledge on the breast cancer receptors and its
association with chemotherapy response in Ghanaian wom-
en can hardly be found. This study sought to investigate the
association between ER, PR and HER2/neu receptors status
and response of breast cancer to chemotherapy given at the
Komfo Anokye Teaching Hospital (KATH) in Kumasi, Gha-
na.
Methods and Materials
Study design
This study was a retrospective cohort study of patients with
breast cancer who received chemotherapy at the oncology
directorate of KATH.
Study site
The two cancer centres in Ghana are located in the two big-
gest cities: Accra which is the capital city and Kumasi which
is the second largest city. Kumasi is located at the central
part of Ghana. The KATH cancer centre serves about 6 out of
the 10 regions in the country. The centre is the referral des-
tination of almost all cancer cases seen at KATH. All breast
cancer patients referred for neo-adjuvant chemotherapy,
adjuvant chemotherapy or radiotherapy are seen at the can-
cer centre. After treatment they are subsequently followed
up at the centre. The oncology centre in Kumasi has a clinic
based registry which started in 2004. On the average 250
oncological cases are seen every year. Cervical cancer is the
leading cancer recorded, followed by breast cancer.
Study Procedure
Patients who had a primary diagnosis of breast cancer as
evidenced by a biopsy and receiving treatment at the oncol-
ogy directorate of the KATH formed the study population.
To be part of this study, patients should have been on the
neo-adjuvant regimen, had taken four cycles (3 weekly) and
with TNM stage T3-T4B, N0-N2, and M0. Patient`s with
co-morbidities: Hypertension, diabetes, asthma, had breaks
in receiving chemotherapy or previous pathology on the
breast other than breast cancer were excluded from the
study.
Adriamycin (60mg/m2) and cyclophosphamide (600mg/m2)
through intravenous bolus injections is the standard
neo-adjuvant chemotherapy given at the centre. Patients
with incomplete clinical response or no response at all after
first line Adriamycin and cyclophosphamide were offered a
second line paclitaxel 170mg/m2 I.V route plus capecitabine
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1000mg/m2 oral. The Response Evaluation Criteria In Solid
Tumour (RECIST 1.0) was used to measure clinical re-
sponse.26 Clinical examination using ruler/tape measure was
used to assess the tumor size before and after chemotherapy.
Between 2009 and 2012, 400 breast cancer cases were seen,
210 of them had received neo-adjuvant chemotherapy. Out
of these 91 patients qualified for inclusion into the study.
Reference numbers on the patients chart were used to trace
the pathology reports per patient from the pathology de-
partment. Report included histological description of the
tumour, macro and micro descriptions and ER/PR,
HER2/neu results.
Data capture
A pre-designed data collection sheet capturing information
such as the menopausal status, parity, age, histological type
ER, PR, HER2/neu expression and treatment history was
used to capture data from the patients’ charts. An electronic
database designed using Epiinfo version 3.2.2 to capture all
the information on the datasheet was designed and the data
double entered. This was compared on regular basis to iden-
tify anomalous data and figures and corrections made.
Statistical analysis
Statistical analysis was carried out using Stata SE 12.1. The
prevalence of the various receptors and treatment outcomes
were analysed and presented as proportions with their bi-
nomial exact confidence intervals. Trends in the various
associated parameters such as the age grouping and remission
status were determined using the chi-square test for trend.
To determine the relationship between the various receptor
status and outcome, an age adjusted odds ratios (OR) with
their 95% confidence intervals and associated p-values were
determined using a logistic regression as receptor status and
outcome of the first line were both associated with age. For
all analysis a two-sided p-value of < 0.05 was considered
statistically significant.
Ethical considerations
Ethical Permission was granted by the Committee of Human
Research Publication and Ethics, Kwame Nkrumah Univer-
sity of Science and Technology, Kumasi, Ghana.
Results
In all 91 patients with breast cancer were included in the
study. All patients completed the first line treatment succes-
sively with 36 (38.3%, 95% CI: 28.5 to 48.9) going into com-
plete remission (Figure 1). The rest were then put through
second line treatment with 34 (58.6%, 95% CI: 44.9 to 71.4)
of them going into complete remission. After both first and
second line treatment a total of 70 (74.5%, 95% CI: 64.4 to
82.9) had gone into complete remission.
Most 58 (61.7%) were between 41 and 60 years with the
youngest being 30 years and the oldest 76 years (Table 1).
The age grouping showed an increasing trend (p = 0.002)
towards better chance of remission after first line treatment
with proportions of those going into remission being 5.6%
(1/18), 43.1% (25/58) and 55.6% (10/18) for the 30-40 years,
41-60 years and 61-76 years groups respectively. Complete
remission after second line treatment was not associated
with age (trend p = 0.259) though it decreased with increas-
ing age with proportions going into of complete remission of
70.6% (12/17), 54.6% (18/33) and 50.0% (4/8) for the age
ranges of 30-40 years, 41-60 years and 61-76 years groups
respectively.
FIG. 1: Flow chart of patient treatments and outcomes.
The mean (SD) parity of the patients was 4.1 (1.8) with most
(44, 46.8%) having 3 to 4 children. Also most of the patients
were pre-menopausal.
The prevalence of ER, PR, HER2/neu and TNBC were 34.0%
(95% CI: 24.6 to 44.5), 20.2% (95% CI: 12.6 to 29.7), 8.5%
(95% CI: 3.7 to 16.1) and 59.6% (95%CI: 48.9 to 69.6) re-
spectively. All patients with PR positive breast cancer also
were ER positive. No significant relationship in terms of
trend or difference in proportions between parity and men-
opausal status on one hand and the presence or absence of
the receptors was detected (Table 1). However there was a
significant trend (p = 0.036) of the proportion of patients
with ER getting higher with increasing age. Also TNBC was
marginally (p = 0.095) related to age with it being more
common in younger age groups.
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TABLE 1: Distribution of age, parity, menopausal stage and receptor status.
Hormone/Receptor status n (%)
Characteristic N (%) ER PR HER2/neu TNBC
Age (yrs)
30-40
41-60
61-76
18 (19.1) 3 (17.7) 2 (11.1) 1 (5.6) 14 (77.8)
58 (61.7) 20 (34.5) 12 (20.7) 7 (12.1) 33 (56.9)
18 (19.2) 9 (50.0) 5 (27.8) 0 (0.0) 9   (50.0)
p-value (proportion)
p-value (trend)
0.107 0.456 0.244 0.189
0.036 0.216 0.552 0.091
Parity
0-2
3-4
>=5
14 (14.9) 6 (42.9) 4 (28.6) 2 (14.3) 7 (50.0)
44 (46.8) 16 (36.4) 10 (22.7) 3 (6.8) 26 (59.1)
36 (38.3) 10 (27.8) 5 (13.9) 3 (8.3) 23 (63.9)
p-value (proportion)
p-value (trend)
0.544 0.433 0.683 0.665
0.274 0.202 0.642 0.381
Menopausal status
Pre-menopause
Menopause
Post-menopause
46 (48.9) 12 (26.1) 7 (15.2) 5 (10.9) 30 (65.2)
14 (14.9) 5 (35.7) 2 (14.3) 0 (0.0) 9 (64.3)
34 (36.2) 15 (44.1) 10 (29.4) 3 (8.8) 17 (50.0)
p-value (proportion)
p-value (trend)
0.240 0.247 0.441 0.362
0.244 0.129 0.694 0.181
TABLE 2: Relationship between tumor staging and receptor status.
Receptor n (%)
Marker/receptor ER PR HER2/neu TNBC
Nodal staging
N0 5 (15.6) 2 (10.5) 1 (12.5) 7 (12.5)
N1 19 (59.4) 13 (68.4) 2 (25.0) 24 (42.9)
N2 8 (25.0) 29 (21.1) 4 (50.0) 18 (32.1)
N3 0 (0.0) 0 (0.0) 0 (0.0) 7 (12.6)
T- staging
1 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8)
2 5 (15.6) 3 (15.8) 0 (0.0) 10 (17.9)
3 5 (15.6) 0 (0.0) 2 (25.0) 5 (8.9)
4b 15 (46.9) 11 (57.9) 4 (50.0) 25 (44.6)
4c 5 (15.6) 4 (21.1) 2 (25.0) 14 (25.0)
4d 2 (6.3) 1 (5.3) 0 (0.0) 1 (1.8)
Grade
1 5 (15.6) 1 (5.3) 2 (25.0) 4 (7.1)
2 21 (65.6) 14 (73.7) 3 (37.5) 18 (32.2)
3 6 (18.8) 4 (21.0) 3 (37.5) 34 (60.7)
TABLE 3: Relationship between receptor status and post treatment complete remission.
N (%)
Marker/receptor status Non-remission Remission OR* (95%CI) p-value
First line treatment
Estrogen 7 (12.1) 25(69.4) 15.7 (5.2 - 47.3) <0.001
Progesterone 4 (6.9) 15 (41.7) 9.4 (2.7 - 33.4) 0.001
Her2Neu
TNBC
5 (8.6)
47 (81.0)
3 (8.3)
9 (25.0)
1.1 (0.2 - 5.3)
0.1 (0.0 - 0.2)
0.868
<0.001
Second line treatment
Estrogen 6 (25.0) 1 (2.9) 0.1 (0.0 - 0.8) 0.033
Progesterone 4 (16.7) 0 (0.0) - -
Her2Neu 3 (12.5) 2 (5.9) 0.4 (0.1 - 2.7) 0.363
TNBC 16 (66.7) 31 (91.2) 5.2 (1.2 - 22.5) 0.027
Combined first & second line treatment
Estrogen 6 (25.0) 26 (37.1) 1.6 (0.6 - 4.7) 0.380
Progesterone 4 (16.7) 15 (21.4) 1.3 (0.4 - 4.3) 0.722
Her2Neu 3 (12.5) 5 (7.1) 0.6 (0.1 - 2.5) 0.451
TNBC 16 (66.7) 40 (57.1) 0.7 (0.3 - 2.0) 0.531
* OR adjusted for age
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The presence of ER or PR were good predictors of remission
after the first line treatment with respective age adjusted
odds of 15.7 (95% CI: 5.2 to 47.3, p < 0.001) and 9.4 (95% CI:
2.7 to 33.4, p = 0.001). TNBC on the other hand predicted
significantly poor outcome (OR: 0.1, 95% CI: 0.0 to 0.2, p <
0.001) after failed first line treatment (Table 3). This rela-
tionship seem to be reversed in those who went ahead to
receive the second line treatment. Here, none of the 4 PR
receptor positive persons went into remission. Also ER posi-
tivity was a predictor of poorer prognosis with an age ad-
justed OR of 0.1 (95% CI: 0.0 to 0.8, p = 0.033). On the other
hand TNBC was associated with a better prognosis with an
age adjusted OR of 5.2 (95CI: 1.2 to 22.5, p = 0.027). There
was no significant relationship observed between HER2/neu
and the response to chemotherapy. Also after combined first
and second line treatment outcomes, presence or absence of
any receptor status was not a predictor of remission.
Discussion
The prevalence of ER from our study was 34.0%. In a study
done by Ohene Yeboah and Adjei, of 68 breast cancer cases
47% were ER positive.27 Yanney et al. 2008 also showed 43%
ER positivity in 74 tumours.28These two studies in addition
to our findings seem to show that ER positive breast cancer
may be on a low side in Ghana. The use of tamoxifen (hor-
monal therapy) targets ER; and it has been shown to reduce
breast cancer mortality by about a third throughout the last
15 years.29 Low prevalence of ER positive breast cancer may
have a negative impact on the prognosis of the Ghanaian
women with breast cancer.
Eighty four percent of the patients with breast cancer who
were ER positive had lymph node involvement (Table 2)
with all being either grade 2 or 3. These findings may sup-
port the fact that breast cancers among people of African
descent are more aggressive histologically and clinically.30
Proportion of pre-menopausal patients with progesterone
positivity was lesser than post-menopausal patients in our
study. Perhaps a larger sample size as the study done by
Clark et al. would be needed to make a fair comparison. Sim-
ilar to ER, PR positivity predicts a good response to first line
Adriamycin and cyclophosphamide according to our study.
Allegra in his study showed that ER and PR were important
predictors of response to chemotherapy in breast cancer.31
HER2/neu immuno-expression was positive in 67.8% of
breast cancer in people of the middle Euphrates region of
Iraq.32 17.5% of the HER2/neu positive tumours was also
found in Jordan in a study done by Sughayer et al. in
2006.33With 46 Japanese patients, Sawaki et al. recorded a
proportion of 50% HER2/neu positive tumours.34 Ohene
Yeboah and Agyei found 20.3% of HER2/neu positive breast
cancer patients in Ghana. We report of 8.5% of HER2/neu in
our study. Seven percent of patients in our study who were
HER2/neu positive had lymph node positive disease. Ac-
cording to Tokatli et al. in 2005 there is a significant associa-
tion between HER2/neu and increasing number of involved
nodes.35 They evaluated the prognostic significance of
HER2/neu over expression in hormone receptor and axillary
lymph node positive breast cancer in a single institution and
concluded that for node positive patients HER2/neu over
expression was a significant predictor of disease free survival.
Coupled with our study it may possibly imply that the
HER2/neu expression in node positive breast cancer patients
in Ghana is low. Thus the majority of breast cancer patients
seen in Ghana have nodal positive disease, but the low
HER2/neu expressions may relatively predict a good progno-
sis.
HER2/neu expression and inexpression in breast cancer tu-
mours does not seem to have any effect on chemotherapy
response, probably because of its low prevalence in our
study. To define the effect of HER2/neu oncogene overex-
pression on sensitivity to chemotherapeutic drugs, Pegram et
al 36 did not find any difference in terms of response to
chemotherapy between tumours with and without
HER2/neu expression. We found similar results in our study;
HER2/neu did not favour good or no response to first line
Adriamycin and cyclophosphamide. This implies that
HER2/neu may not be used as a predictive marker for first
line chemotherapy response.
Conclusion
Most patients with breast cancer in Kumasi are TNBC with
about a third being ER positive. HER2/Neu overexpression
was relatively uncommon. ER and PR positivity portends
good prognosis after first line treatment but for patients who
do not go into remission also do not do well on second line
treatment. On the other hand persons with TNBC had poor-
er outcome after first line treatment but better outcome in
terms of remission after the second line treatment.
HER2/Neu overexpression was not associated with complete
remission in our population.
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